Key Insights

Highlights

Treatment Research

2 treatments under study, led by Everolimus

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07865130Phase 1Not Yet Recruiting

Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

Showing all 1 trials

Research Network

Common Treatments

  • Everolimus1
  • Rvu1201

Active Sponsors

  • Bożenna Dembowska Bagińska1
  • Instytut Pomnik Centrum Zdrowia Dziecka1
  • Ryvu Therapeutics SA1

Top Investigators

Related Conditions

  • Medulloblastoma1
  • Medulloblastoma Recurrent1

Activity Timeline